SJM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SJM is a reasonable long-term hold, but it is not a strong buy right now for a beginner who wants to invest immediately and does not want to wait for a better entry. The stock has supportive dividend and earnings momentum, but the current price is sitting near near-term resistance and the short-term technical setup is mixed. For a long-term investor with $50,000-$100,000, I would not chase it here; I would hold off unless the price pulls back or the stock clearly breaks above resistance with follow-through.
SJM is still in a broader bullish trend because SMA_5 > SMA_20 > SMA_200, which supports the long-term uptrend. However, momentum is not fully aligned: the MACD histogram is slightly negative at -0.057, indicating short-term momentum is fading even though it is contracting. RSI_6 at 63.839 is neutral-to-bullish, not overbought, but not an aggressive entry signal either. Price at 116.06 is essentially at R1 116.269, so the stock is trading right under short-term resistance rather than at a clear discount. Key support sits at 112.384, with stronger support lower near 108.499. Overall: bullish long-term structure, but near-term upside looks limited without a breakout.
["Hedgeye added SJM as a long idea and sees upside of roughly one-third over the next year.", "The company has raised its dividend for 28 consecutive years, which supports long-term investor appeal.", "Recent news reports 6% sales growth and 20% adjusted earnings growth year over year.", "Free cash flow reached $1.2 billion, indicating solid cash generation.", "Analysts remain generally constructive overall, with multiple Buy/Outperform ratings and higher price targets around $125-$134."]
["Several analysts have recently cut price targets, showing some caution around FY27 outlook and cost inflation.", "Morgan Stanley and other firms highlighted incremental cost pressure and weaker forward estimates.", "Deutsche Bank and Stifel maintain Hold ratings, reflecting a split Wall Street view.", "The stock is trading near short-term resistance, limiting immediate upside.", "Pattern-based stock trend data suggests a slight negative drift over the next week and month."]
The latest quarter context available from the news suggests strong operational performance in the most recent reported season, with 6% sales growth and 20% growth in adjusted earnings. Free cash flow of $1.2 billion is also a positive sign for a consumer staples company. The latest quarter season is the fiscal Q4 report referenced ahead of and around June 9, and the market appears to have responded well to the company's earnings strength and dividend increase. The main concern is that some analysts still expect fiscal 2027 net sales declines, even though earnings are projected to rise 7% to 12%.
Wall Street is mixed but slightly positive. Bullish voices include UBS, BofA, JPMorgan, Bernstein, Evercore ISI, and Hedgeye, with several Buy or Outperform/Overweight calls and price targets mostly in the $117-$134 range. Bearish or cautious voices include Deutsche Bank, Stifel, and Morgan Stanley, which have Hold/Equal Weight ratings and lower price targets around $95-$106. The overall direction of ratings is still constructive, but recent target changes show some downward revisions due to inflation and softer forward estimates. Net view: pros see a defensive quality name with dividend support and earnings recovery potential, while cons worry about costs, weaker volume growth, and limited near-term sales upside.
